Affinity-assisted egg white fractionation via peptide-protein association

Overview

This technology is a new egg white fractionation platform that uses transient peptide–protein association to separate egg white into two value-added fractions with different functional and sensory profiles. By converting peptide hydrophobicity into a membrane-separation handle, the process addresses common limitations of single egg white protein hydrolysates—such as bitter hydrophobic peptides and loss of foaming or emulsification—while retaining the nutritional and functional benefits of intact egg white proteins.

The platform yields two complementary products:

• A soluble, low-viscosity peptide-rich permeate suitable for ready-to-drink (RTD) beverages and clinical nutrition applications.
• An egg white protein–peptide coassembly retentate designed for frozen and aerated food products, carrying a defined peptide payload while aiming to match or improve application-relevant functionality compared with untreated or commercial egg white protein.

This approach targets a clear market need: turning egg white into differentiated protein ingredients with distinct applications, while avoiding the bitterness and functionality losses typical of conventional hydrolysates.

Technical specifications

Core process:

• Controlled enzymatic hydrolysis of egg white protein creates hydrolysate peptides with varying hydrophobicity.
• The intact egg white protein fraction is briefly pH-shifted (starting in the pH 11.0–11.5 range, with pH 13 as an upper bound) to expose candidate binding sites.
• Hydrolysate and pH-shifted proteins are combined at a controlled ratio. Prompt neutralization and optional high-pressure homogenization (HPH) are used to sequence contact and reassembly.
• Crossflow ultrafiltration/diafiltration then separates the mixture based on effective molecular size:
  • Hydrophilic, unbound peptides are recovered in the permeate.
  • Peptide-loaded egg white protein coassemblies are retained in the retentate.

Key distinguishing features:

• Uses size-based membrane separation to achieve a functionality-based split, through peptide–protein association rather than simple molecular weight filtration alone.
• Does not assume hydrophobic or bitterness removal; the process is designed to demonstrate reduced free peptide concentration and reduced sensory accessibility.
• Includes orthogonal association assays, peptide-level mass balance, and mechanism-isolating controls to validate whether the bound-versus-unbound shift is genuine.
• Process can vary feed ratios, addition order, HPH timing/energy, and membrane cutoff to optimize performance.

Target performance metrics:

• Hydrophobic-peptide depletion from the permeate should exceed the overall peptide depletion, while meeting flux, water use, and recovery targets.
• Success criteria include at least 85% recovery during membrane fractionation.
• Product testing covers bitterness, solubility, viscosity, heat stability, foaming/emulsification, yield, throughput, and cost of goods.

Technology readiness level

This platform is at an early-stage research phase. The underlying hypothesis has been defined and an experimental validation plan is structured in four phases:

1. Refined safe activation parameters that pass food-safety and functionality gates.
2. Verification of affinity and effective-size shift through feeding systems and orthogonal controls.
3. Membrane fractionation optimization.
4. Translation into spray-dried ingredients and testing in RTD/clinical and frozen/aerated food models.

Currently, the technology has not yet completed these validation stages. The proposed development plan is designed to generate independent evidence of the association mechanism, membrane separation performance, and finished-product functionality before scale-up.